NanoMedical Systems develops novel drug-delivery devices based on its proprietary nStrada™ nanofluidics platform for sustained release of chronic therapies. The nStrada Drug Delivery Platform utilizes state-of-the-art semiconductor manufacturing methods and biocompatible materials and features a tunable high-density array of precision nanochannels that regulates the delivery of drug molecules from an internal reservoir. No power or moving parts are required for long-term constant delivery.
Austin, United States
Founded in 2006
11-50 Employees
Working industry
Nanotechnology
Type of company
Manufacturer
Ownership structure
Privately Held
Locations
1 Headquarter
Specialised areas
The New Pharma, Silicon Nanochannels, cGMP Manufacturing - Silicon Devices, Biotechnology, Bioanalytical Sample Preparation, Sustained Drug Delivery, Drug Delivery, Nanotechnology transforming Drug Delivery, Peptide Enhancement, Professional and Commercial Equipment and Supplies Merchant Wholesalers
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
NanoMedical Systems operates in 1 country around the world
Get an overview of the locations of NanoMedical Systems
Location
Country
State
City
Headquarter
United States
Texas
Austin
Some frequent questions that have been asked about NanoMedical Systems
Where is NanoMedical Systems located?
The company headquarter of NanoMedical Systems is located in Austin, Texas, United States. It's worth noting, that the company may have more locations
How many employees does NanoMedical Systems approximately have?
As of the latest available information NanoMedical Systems has around 11-50 employees worldwide.
When was NanoMedical Systems founded?
NanoMedical Systems was founded in 2006
In which industries does NanoMedical Systems mainly work?
The company NanoMedical Systems has it's main focus in the industries of Nanotechnology
Check out some interesting alternative companies to NanoMedical Systems
Kettleby Nano Therapeutics Europe GmbH
Berlin, Germany
1-10 Employees
2019
The heart of our Mission beats with purpose, propelling us to conquer uncharted territories in medical innovation. Our Vision propels us forward, urging us to reach new heights in the realm of medical technology. We are committed to develop novel therapies to address unmet medical needs and provide greater efficacy and safety for patients. Ltd., established in 2011, is a prominent player in the global Vascular Stents, Stent Systems & Support Devices. Led by experienced professionals, the company leverages cutting-edge technology and Nano Science to provide provides enhanced and safe therapies. Nano Therapeutics is a globally recognized leader in the Stent and Support Devices sector. With a global presence in over nine countries, Nano Therapeutics continues to grow, delivering high-quality medical devices and healthcare products to healthcare professionals and patients worldwide. Our state-of-the-art manufacturing facility, located in Surat, India, spans an impressive 16,000 square feet and upholds the stringent requirements of ISO 13485.
Westwood Bioscience Inc
Los Angeles, United States
1-10 Employees
2018
Nanomedicine is a newly evolving field in which the functions and features of nanoscale objects and systems are used for improved diagnostics, imaging, therapeutics and regenerative medicine.Nanotherapeutics include the use of nanocarriers for drug delivery, with the potential to improve the pharmacokinetics, biodistribution, tissue concentrations and efficacy over the free drug. In addition, encapsulated drug delivery can also reduce the systemic biodistribution and toxicity of potentially hazardous drugs such as chemotherapeutics.The Silicasome is an example of an encapsulated nanocarrier, which is comprised of a mesoporous silica nanoparticle core with a lot of drug packaging space, and surrounded by a lipid bilayer. Westwood Bioscience, Inc., incorporated in 2017, are developing a new nanocarrier technology for improved delivery of chemotherapeutic agents to pancreas and colon cancer tuned to achieve improved efficacy, while reducing toxicity.Work led by Drs. This development has attracted significant attention in the field of pancreas cancer chemotherapy, as the Westwood nanocarrier is capable of delivering a single or ratiometric combination of chemotherapeutic agents to the cancer site, with the ability to overcome the drug resistant in stroma, improve efficacy and improve the toxicity over other nanocarriers used for treating this disease.
Integrated Nanotherapeutics Inc.
Burnaby, Canada
1-10 Employees
-
In addition, we are advancing a therapeutic platform that induces antigen-specific tolerance to treat autoimmune diseases. We are determined to develop innovative drug delivery systems that enable the full therapeutic potential of various compounds as safe and effective nanomedicines. Integrated Nanotherapeutics (INT) is a biotech company in Vancouver, Canada focused on using nanotechnology to uncover and maximize the therapeutic potential of many drugs. Our proprietary drug delivery platform technology can deliver any type of drug modality in lipid nanoparticles (LNPs), either alone or in combination, to disease tissues and cells. Integrated Nanotherapeutics is founded by a team of world-class scientists with multi-disciplinary skills in basic science, preclinical research, drug development, and commercialization of therapeutics. We have collectively over 100 years of experience in lipid nanoparticle (LNP) science and drug development. We strive to become the leading nanomedicines company in the world and provide advanced, first-in-class therapies to many people. Our versatile drug delivery platform allows the incorporation of virtually any small molecule and/or biologic into lipid nanoparticles (LNPs).
NanoSiliCal Devices Srl
Rende, Italy
1-10 Employees
2014
We produce highly intelligent, multifunctional, mesoporous silica micro and nano-systems to be exploited in target therapy. Our products technology is based on science of materials, providing nanostructured particles that can be administered intravenously, and, through the bloodstream, they can reach cancer cells, interact with them through a biological process and release a drug within. NanoSiliCal Devices is a spin-off at the University of Calabria, founded in 2014 by the research team made up by Prof. It aims to develop nanostructured products that may be exploited as smart anticancer therapies, basing its activities on the results of experimental studies, gained in the last 10 years, that haveled to several International Patent Applications and publications on international journals with high impact factor. Research and development activities are the aim of the innovative nature of NanoSiliCal Devices. NanoSiliCal Devices is the result of several studies based on properties, synthesis, characterization and biological validation of mesoporous silicas.These studies involve a modular method of synthesis of mesoporous silica based micro-and nano-systems that could be used for drug delivery. This is an excellent drug delivery system based on Receptor-specific ligand on the external surface and drug inside the pores. The main application of our products is the targeted chemotherapy, whose main purpose is to reduce drug doses, to improve therapeutic efficacy and to reduce toxic and side effects.
NanoMedTrix LLC
Coralville, United States
1-10 Employees
2012
Our mission is to develop and deliver innovative nanoparticles that improve the lives of patients around the world. We are committed to providing the highest quality products and services, and to working with our partners to advance the field of nanotechnology. At NanoMedTrix, multi-pronged efforts are underway to increase manufacturing capacity and improve potential toxicity inherent to systemic therapeutic delivery. NanoMedtrix has reached scaling-up levels for commercial applications, including manufacturing strategies for purities, excluding toxic materials, and ready-to-GMP preparations. Our products have been tested for tumoricidal effects with various drug classes such as taxanes, antineoplastic antibiotics, antimetabolite agents, and anti-angiogenic. NanoMedtrix has, from the start, answered the demand and focused on combining powerful tools to simultaneously monitor and selectively treat a wide range of diseases witheffective drugs and new untrialed drugs. Recently, we developed partnerships with the clinical and commercial sectors. We developed models for bladder cancer in two pre-clinical models (mice and dogs) and are poised to begin investigations and sample preparation (scale up and pharmaceutic preps) for first in human.
Nanomerics Ltd
London, United Kingdom
1-10 Employees
2010
Nanomerics is a privately held speciality pharmaceutics company based in London, UK. Nanomerics is focused on the development of better medicines - rather than better drugs - reducing the typical development costs, resources and timelines. Nanomerics has a pipeline of its own as well as partnered programs addressing important areas of medical need, including non-addictive pain therapies and degenerative CNS conditions, therapies to preserve eye sight, or medicines where tablets replace intravenous administrations or applications that minimise the risk of viral infections, e.g. Nanomerics develops precision medicines that address medical need by focusing on reducing the typical development costs, resources and timelines. Nanomerics' proprietary technology addresses medical and non-medical applications with a focus on conditions at the front and back of the eye, CNS conditions and challenging oral active pharmaceutical ingredients (APIs). Nanomerics has a pipeline of its own as well as partnered programs addressing important areas of medical need and orphan indications. Nanomerics' creates better medicines by enhancing and repurposing existing drugs (and new chemical entities - NCEs) using its proprietary platform technologies. Nanomerics has a pipeline of its own as well as partnered programs addressing important areas of medical need.